— Know what they know.
Not Investment Advice

KYMR Short Interest

Kymera Therapeutics, Inc.
1W: +6.3% 1M: +2.6% 3M: +8.2% YTD: +57.8% 1Y: +98.8% 3Y: +865.9% 5Y: +112.9%
$117.57
+2.73 (+2.38%)
After Hours: $113.62 (-3.94, -3.36%)
Weekly Expected Move ±5.5%
$99 $105 $111 $117 $123
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 60 · $9.4B mcap · 66M float · 1.30% daily turnover · Short 57% of daily vol
Credit Risk of going bust: lower than 78% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Short Volume Summary

2026-10-26
83.5%
Short Ratio
of total volume
63.9%
20-Day Avg
63.9%
50-Day Avg
▼ Falling
5-Day Trend
0.1M
Short Volume
0.2M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 137,939 166,050 83.1%
NYSE 8,820 9,870 89.4%
BATS 554 566 97.9%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms